RGC Regencell Bioscience Holdings Ltd Annual reports only
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1829667
Financial factors as of 2026-06-30 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-226.5%
TTM EPS YoY-229.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-128.5%
ROA-114.2%
ROIC (approx.)-1,159.2%
Asset turnover—
Leverage & solvency
Liabilities / assets9.4%
Debt / equity0.00x
Current ratio10.77x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.66x
Accruals ratio-39.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-06-30 | FY20252025-06-30 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $1.30M | $948,289 |
| SG&A expense | $10.42M | $2.81M |
| Operating income | -$11.72M | -$3.77M |
| Pretax income | -$11.70M | -$3.58M |
| Net income | -$11.70M | -$3.58M |
| EBITDA | -$11.64M | -$3.69M |
| EPS (basic) | -2.37 | -0.72 |
| EPS (diluted) | -2.37 | -0.72 |
| Weighted avg. shares (diluted) | 494.60M | 494.49M |
| Balance sheet | ||
| Cash & equivalents | $14.19M | $2.42M |
| Short-term investments | — | $2.48M |
| Current assets | $14.22M | $4.90M |
| PP&E, net | $135,112 | $215,434 |
| Total assets | $14.73M | $5.76M |
| Current liabilities | $1.32M | $663,673 |
| Total liabilities | $1.38M | $895,308 |
| Shareholders' equity | $13.35M | $4.86M |
| Shares outstanding | 495.88M | 494.49M |
| Cash flow statement | ||
| Operating cash flow | -$7.70M | -$3.11M |
| Capital expenditure | — | $152,689 |
| Free cash flow | — | -$3.27M |
| Investing cash flow | $2.50M | $2.69M |
| Financing cash flow | $16.95M | — |
| Depreciation & amortization | $80,908 | $77,692 |
| Stock-based compensation | $3.23M | $244,808 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.